AKBA - Akebia Therapeutics, Inc.
NEXT EARNINGS:
Feb 26, 2026
(in 1 day)
EPS Est: $-0.03
|
Rev Est: $48.4M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$4.00
DETAILS
HIGH:
$4.00
LOW:
$4.00
MEDIAN:
$4.00
CONSENSUS:
$4.00
UPSIDE:
222.58%
Market Cap:
329.05M
Volume:
2,364,386
Avg Volume:
3,209,448
52 Week Range:
1.14-4.079
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.37
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
181
IPO Date:
2014-03-20
EPS (TTM):
-0.33
P/E Ratio:
-5.77
Revenue (TTM):
160.18M
Total Assets:
220.67M
Total Debt:
188.73M
Cash & Equiv:
51.87M
Rev Growth (5Y):
-13.7%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-36.7%
Debt/Equity:
-3.84
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-10 | $0.00 | $-0.06 | +103.3% | $58.8M | $48.4M | +21.5% |
| 2025-08-07 | $0.00 | $-0.02 | +104.6% | $62.5M | $47.9M | +30.5% |
| 2025-05-08 | $0.03 | $-0.03 | +200.0% | $57.3M | $50.8M | +12.9% |
| 2025-03-13 | $-0.10 | $-0.05 | -100.0% | $46.5M | $37.4M | +24.3% |
| 2024-11-07 | $-0.10 | $-0.05 | -100.0% | $37.4M | $40.9M | -8.5% |
| 2024-08-08 | $-0.04 | $-0.06 | +33.3% | $43.6M | $49.5M | -11.7% |
| 2024-05-09 | $-0.09 | $-0.09 | 0.0% | $32.6M | $49.5M | -34.1% |
| 2024-03-14 | $0.00 | $0.00 | +100.0% | $56.2M | $55.4M | +1.5% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 160.18M | 194.62M | 292.48M | 211.65M | 294.64M | 335.00M | 207.74M | 177.98M | 1.53M | 0 | 0 | 0 |
| Net Income | (69.41M) | (51.92M) | (94.23M) | (282.02M) | (384.84M) | (279.66M) | (171.90M) | (76.91M) | (135.75M) | (60.72M) | (37.03M) | (13.17M) |
| EPS | -0.33 | -0.28 | -0.58 | -1.48 | -2.53 | -2.36 | -1.47 | -1.77 | -3.60 | -2.29 | -2.40 | -0.68 |
| Total Assets | 220.67M | 241.70M | 356.05M | 529.35M | 644.14M | 771.20M | 996.54M | 364.25M | 300.22M | 142.94M | 111.00M | 34.66M |
| Total Debt | 188.73M | 104.18M | 99.78M | 136.05M | 126.28M | 108.32M | 15.00M | 0 | 0 | 14,000 | 0 | 11,916 |
| Cash & Equivalents | 51.87M | 42.92M | 90.47M | 149.80M | 229.09M | 147.71M | 104.64M | 70.16M | 187.34M | 49.78M | 32.78M | 21.22M |
| Operating Cash Flow | (40.66M) | (23.38M) | (73.15M) | (252.97M) | (110.39M) | (257.44M) | (97.49M) | (56.16M) | 57.91M | (52.41M) | (27.48M) | (11.33M) |
| Free Cash Flow | (40.69M) | (23.38M) | (73.27M) | (253.02M) | (110.70M) | (264.10M) | (99.10M) | (57.78M) | 55.24M | (52.82M) | (27.71M) | (11.35M) |
| FCF per Share | -0.19 | -0.12 | -0.40 | -1.52 | -0.80 | -2.23 | -0.85 | -1.33 | 1.46 | -2.00 | -1.80 | -0.76 |
| Book Value | (49.19M) | (30.58M) | 5.23M | 74.01M | 247.62M | 394.76M | 635.93M | 119.33M | 68.12M | 131.00M | 104.08M | 30.76M |
| Cash & ST Investments | 51.87M | 42.92M | 90.47M | 149.80M | 269.08M | 147.96M | 321.64M | 317.79M | 260.34M | 138.45M | 108.92M | 32.56M |
| ROC Equity | N/A | N/A | -18.02 | -3.81 | -1.55 | -0.71 | -0.27 | -0.64 | -1.99 | -0.46 | -0.36 | -0.43 |